z-logo
open-access-imgOpen Access
The Co-Expression of Kallikrein 5 and Kallikrein 7 Associates with Poor Survival in Non-HPV Oral Squamous-Cell Carcinoma
Author(s) -
Frank K.J. Leusink,
P. J. van Diest,
Michael Frank,
Roel Broekhuizen,
W.W. Braunius,
Sander R. van Hooff,
Stefan M. Willems,
R. Koole
Publication year - 2015
Publication title -
pathobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 53
eISSN - 1423-0291
pISSN - 1015-2008
DOI - 10.1159/000381904
Subject(s) - kallikrein , medicine , oncology , cancer research , cancer , biology , biochemistry , enzyme
Oral squamous-cell carcinoma (OSCC) still has a poor prognosis. Lymph node metastasis (LNM) is a major determinant of treatment decisions and prognosis. Serine protease inhibitor Kazal-type 5 (SPINK5) is the inhibitor of kallikrein 5 (KLK5) and KLK7. SPINK5, KLK5 and KLK7 are three of the genes of a recently validated LNM-predicting gene expression profile in OSCC. This study evaluates their clinicopathological role and value as biomarkers in OSCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here